Department of Orthopaedic Surgery, University of Virginia, Charlottesville, Virginia; Department of Orthopaedic Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, China.
Department of Orthopaedic Surgery, University of Virginia, Charlottesville, Virginia.
J Arthroplasty. 2023 Dec;38(12):2650-2654. doi: 10.1016/j.arth.2023.05.088. Epub 2023 Jun 8.
Historically, Charcot neuroarthropathy hip (CNH) was deemed a contraindication for total hip arthroplasty (THA). However, as implant design and surgical techniques advance, THA for CNH has been performed and documented in literature. Information regarding the outcomes of THA for CNH is limited. The objective of the study was to assess outcomes following THA in patients who have CNH.
Patients who have CNH underwent primary THA and had at least 2 years of follow-up were identified in a national insurance database. For comparison, a 1:10 matched control cohort of patients who did not have CNH was created based on age, sex, and relevant comorbidities. Eight hundred and ninety-five CNH patients who underwent primary THA were compared to 8,785 controls. Medical outcomes, emergency department visits, hospital readmissions, and surgical outcomes including revisions between cohorts were evaluated using multivariate logistic regressions.
The CNH patients were found to have higher risks of 90-day wound complications (P = .014), periprosthetic joint infection (P = .013) (P = .021), dislocation (P < .001) (P < .001), aseptic loosening (P = .040) (P = .002), periprosthetic fracture (P = .003) (P < .001), and revision (P < .001) (P < .001) at 1-year and 2-year follow-up, respectively.
While patients who have CNH are at a higher risk of wound and implant-related complications, they are comparatively lower than previously reported in literature. Orthopaedic surgeons should be cognizant of the increased risk in this population to provide appropriate preoperative counseling and enhanced perioperative medical management.
从历史上看,夏科氏神经关节病髋(CNH)被认为是全髋关节置换术(THA)的禁忌证。然而,随着植入物设计和手术技术的进步,已经有文献报道了 CNH 患者行 THA 的情况。关于 CNH 患者行 THA 后结果的信息有限。本研究的目的是评估 CNH 患者行 THA 后的结果。
在国家保险数据库中,确定了接受 CNH 初次 THA 且至少有 2 年随访的患者。为了进行比较,根据年龄、性别和相关合并症,创建了 1:10 的 CNH 患者匹配对照组。将 895 例接受初次 THA 的 CNH 患者与 8785 例对照进行比较。使用多变量逻辑回归评估两组之间的医疗结果、急诊就诊、住院再入院和手术结果,包括翻修率。
发现 CNH 患者的 90 天伤口并发症(P =.014)、假体周围关节感染(P =.013)(P =.021)、脱位(P <.001)(P <.001)、无菌性松动(P =.040)(P =.002)、假体周围骨折(P =.003)(P <.001)和翻修(P <.001)(P <.001)的风险更高,分别在 1 年和 2 年随访时。
虽然 CNH 患者有更高的伤口和植入物相关并发症风险,但与文献中的先前报道相比,该风险相对较低。骨科医生应该意识到这一人群的风险增加,以便提供适当的术前咨询和强化围手术期医疗管理。